Allergy Therapeutics PLC
11 May 2005
Schedule 10
NOTIFICATION OF MAJOR INTERSTS IN SHARES
1. Name of Company
Allergy Therapeutics plc
2. Name of shareholder having a major interest
Fidelity International Limited
3. Please state whether notification indicates that it is in
respect of holding of the shareholder names in 2 above or in respect of a
non-beneficial interest or in the case of children under the age of 18
Non-beneficial interest
4. Name of the registered holder(s) and, if more than one
holder, the number of share held by each of them
Nominee/registered name Share held Management Company
JP Morgan, Bournemouth 1,572,100 Fidelity Inv Services Ltd
Bank of New York, Brussels 359,662 Fidelity Pension Mgmnt(FPM)
Bankers Trust London 135,700 FPM
CITIBANK London 128,400 FPM
Clydesdale Bank plc 71,900 FPM
JP Morgan, Bournemouth 288,500 FPM
Mellon Bank 325,400 FPM
Midland Securities Services 74,300 FPM
Northern Trust London 618,500 FPM
State STR BK and TR Co London 227,084 FPM
Brown Bros Harrimn Ltd LUX 650,000 FPM
Bank of New York, Brussels 81,900 FIL
5. Number of shares/amount of stock acquired
650,000
6. Percentage of issued class
1.03%
7. Number of shares/amount of stock disposed
-
8. Percentage of issued class
-
9. Class of security
Ordinary shares
10. Date of transaction
Not notified
11. Date company informed
10th May 2005
12. Total holding following this notification
4,533,446
13. Total percentage holding of issued class following this
notification
7.20%
14. Any additional items
Notifiable interest also comprises of Mr.Edward C. Johnson 3d A principal
Shareholder of Fidelity International Limited
15. Name of contact and telephone number for queries
Ian Postlethwaite - 01903 844721
16. Name and signature of authorised company official responsible
for make this notification
Ian Postlethwaite
Date of notification
10th May 2005
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept liability for error or omission. The
FSA is not liable for any damages (including, without limitation, damages for
loss of business or loss of profits) arising in contract, tort or otherwise from
the use of or inability to use this document, or any material contained in it,
or from any action or decision taken as a result of using this document or any
such material.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.